Want to see KRYS full AI Analyst Report?
KRYS Stock Chart & Stats
$335.19
$7.69(2.35%)
At close: 4:00 PM EDT
$335.19
$7.69(2.35%)
Day’s Range― - ―
52-Week Range$136.73 - $382.54
Previous CloseN/A
Volume520.38K
Average Volume (3M)527.57K
Market Cap
$9.98B
Enterprise Value$10.56K
Total Cash (Recent Filing)$845.63M
Total Debt (Recent Filing)$8.85M
Price to Earnings (P/E)41.9
Beta0.63
Next Earnings
Nov 09, 2026EPS Estimate
1.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.27
Shares Outstanding29,598,837
10 Day Avg. Volume847,932
30 Day Avg. Volume527,571
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)5.85
Price to Sales (P/S)18.34
P/FCF Ratio37.77
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$402.67Price Target Upside20.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)7.47
Revenue Forecast (FY)$501.09M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity And Cash GenerationA >$1.1B cash balance combined with TTM free cash flow of ~$258M provides durable funding for commercialization, trials and regulatory activities without near-term financing. This materially lowers execution and refinancing risk and supports multi-year R&D and launch investments.
Very High Margins And ProfitabilityExtremely high gross margins (95%) and strong TTM net/EBIT margins indicate scalable product economics for VYJUVEK. These durable profit margins create operating leverage as sales grow and provide cash to self-fund pipeline programs and commercial expansion over multiple quarters.
Commercial Penetration And Payer ApprovalsRobust payer engagement and achieving >60% penetration in the diagnosed U.S. DEB patient pool indicate effective commercialization infrastructure. Durable reimbursement approvals and field execution improve predictable recurring revenue and lower patient access friction over time.
Bears Say
International Pricing And Reimbursement UncertaintyPending pricing negotiations (notably Germany) and country-specific access rules create structural timing and cash-flow variability outside the U.S. Delays or unfavorable decisions in major EU markets could materially slow international revenue buildup and strain cross-border commercialization plans.
Small Early-stage Repeat-dose StudiesKey repeat-dose programs rely on very small cohorts, reducing confidence in safety and efficacy signals. This limits predictability for registrational starts and commercial expansion, making multi-quarter pipeline de-risking contingent on tiny datasets that may delay or complicate approvals.
Revenue Concentration In Single ProductCurrent revenue is highly concentrated in VYJUVEK, so payer coverage, prescriber adoption, or safety/production issues could disproportionately affect cash flow. While the platform has pipeline programs, durable diversification is still years away, leaving short-to-mid-term concentration risk.
Krystal Biotech News
KRYS FAQ
What was Krystal Biotech’s price range in the past 12 months?
Krystal Biotech lowest stock price was $136.73 and its highest was $382.54 in the past 12 months.
What is Krystal Biotech’s market cap?
Krystal Biotech’s market cap is $9.98B.
When is Krystal Biotech’s upcoming earnings report date?
Krystal Biotech’s upcoming earnings report date is Nov 09, 2026 which is in 78 days.
How were Krystal Biotech’s earnings last quarter?
Krystal Biotech released its earnings results on Aug 03, 2026. The company reported $1.79 earnings per share for the quarter, beating the consensus estimate of $1.701 by $0.089.
Is Krystal Biotech overvalued?
According to Wall Street analysts Krystal Biotech’s price is currently Undervalued.
Does Krystal Biotech pay dividends?
Krystal Biotech does not currently pay dividends.
What is Krystal Biotech’s EPS estimate?
Krystal Biotech’s EPS estimate is 1.87.
How many shares outstanding does Krystal Biotech have?
Krystal Biotech has 29,598,837 shares outstanding.
What happened to Krystal Biotech’s price movement after its last earnings report?
Krystal Biotech reported an EPS of $1.79 in its last earnings report, beating expectations of $1.701. Following the earnings report the stock price went down -8.369%.
Which hedge fund is a major shareholder of Krystal Biotech?
Currently, no hedge funds are holding shares in KRYS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Krystal Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$402.67 (20.13% Upside)
$402.67 (20.13% Upside)
Blogger Sentiment
Bullish
KRYS Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $23.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
123.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
31.82%
Trailing 12-Months
Company Description
Krystal Biotech
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
KRYS Company Deck
KRYS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong commercial and financial highlights — double‑digit revenue growth (+24% YoY), improved gross margin (95%), expanded U.S. reimbursement (>730 approvals), robust cash (> $1.1B), and advancing clinical programs with several near‑term readouts and encouraging oncology signals. Lowlights were primarily operational and timing risks tied to international pricing/reimbursement (notably a German accrual that depressed reported EMEA revenue), country‑specific access constraints, modest increases in G&A, and the small size/early stage of several repeat‑dose studies. Overall, the positives around revenue, profitability, cash position, and pipeline momentum outweigh the near‑term access and timing headwinds, supporting a constructive outlook.View all KRYS earnings summariesKRYS Stock 12 Month Forecast
Average Price Target
$402.67
▲(20.13% Upside)
Technical Analysis
Ownership Overview
10.99% Insiders
30.30% Mutual Funds
33.56% Other Institutional Investors
2.60% Public Companies and Individual Investors